Source - SMW
Allergy Therapeutics hosted a  satellite symposium at the 36th annual congress of the European Academy of Allergy and Clinical Immunology in Helsinki yesterday.
Chaired by Professor Stephen Durham, four world-leading experts in the field of allergy, pollen, and immunotherapy vaccine delivery, Jorg Kleine-Tebbe, Erika Jensen-Jarolim, Uwe Berger and Tim Higenbottam presented on the strategy, design and considerations involved in creating immunotherapies such as Allergy Therapeutics' flagship product, Pollinex Quattro.  

Berger and Jensen-Jarolim discussed the importance of highlighting relevant allergens and characterising them sufficiently.  

Kleine-Tebbe discussed why successful immunotherapy requires identification of the optimal dose before Phase III studies are begun, before Higenbottam finished the session describing the results recently gained from the group's clinical studies.

At 9:53am: (LON:AGY) Allergy Therapeutics PLC share price was +0.25p at 24.75p